Simcere Pharmaceutical Group (HKSE:02096) 3-Year Revenue Growth Rate : 6.20% (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Simcere Pharmaceutical Group 3-Year Revenue Growth Rate?

Simcere Pharmaceutical Group's Revenue per Share for the six months ended in Dec. 2024 was HK$1.51.

During the past 12 months, Simcere Pharmaceutical Group's average Revenue per Share Growth Rate was 1.40% per year. During the past 3 years, the average Revenue per Share Growth Rate was 6.20% per year. During the past 5 years, the average Revenue per Share Growth Rate was 7.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 8 years, the highest 3-Year average Revenue per Share Growth Rate of Simcere Pharmaceutical Group was 10.60% per year. The lowest was 5.20% per year. And the median was 6.20% per year.

Competitive Comparison of Simcere Pharmaceutical Group's 3-Year Revenue Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Simcere Pharmaceutical Group's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Simcere Pharmaceutical Group's 3-Year Revenue Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Simcere Pharmaceutical Group's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Simcere Pharmaceutical Group's 3-Year Revenue Growth Rate falls into.

Save Embed

;

Save Embed

;

Simcere Pharmaceutical Group 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Simcere Pharmaceutical Group (HKSE:02096) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Simcere Pharmaceutical Group 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Simcere Pharmaceutical Group's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Simcere Pharmaceutical Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Simcere Pharmaceutical Group Ltd (HKSE:02096) » Definitions » 3-Year Revenue Growth Rate

Traded in Other Exchanges

S2P:Germany

Address

No. 699-18, Xuanwu Road, Xuanwu District, Jiangsu, Nanjing, CHN, 210042

Website

https://www.simcere.com

Simcere Pharmaceutical Group Ltd is engaged in the R&D, production, and commercialization of pharmaceuticals focused on generic pharmaceuticals. It has a diversified product portfolio focused on therapeutic areas, including, oncology (including cell therapy), nervous system diseases, autoimmune diseases, and antiinfection. The company's products include Endostar, Enweida, Iremod, Sanbexin and Others.

Executives

Artking Global Limited	2501 Other
Fortune Fountain Investment Limited	2501 Other
Li Shimeng	2501 Other
P&h Holdings Group Ltd.	2501 Other
Peng Suqin	2501 Other
Ren Weidong	2501 Other
Ren Yong	2501 Other
Ren Zhen	2501 Other
Right Wealth Holdings Limited	2501 Other
Simcere Holding Limited	2501 Other
Wang Xi	2501 Other
Simcere Pharmaceutical Holding Limited	2501 Other
Ren Jinsheng	2202 Interest of your spouse
Excel Investments Group Limited	2501 Other
Simcere Investments Group Limited	2501 Other

Simcere Pharmaceutical Group Headlines

No Headlines